MBIO net incomeQ3 2026-$964.0K
MBIO net income was -$964.0K in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$468.0K a year earlier. For the full fiscal 2025 it was -$1.92M, compared with -$15.75M in fiscal 2024.
Mustang Bio Inc. (MBIO) financials
For the twelve months ended Sep 30, 2026, Mustang Bio Inc. reported -$3.53M of net income.
- Net income, TTM
- -$3.53M
- Cash
- $14.28M
- Market cap
- $3.4M
FY2016FY2025
FY2017FY2024
MBIO revenue and earnings growth
MBIO EPSQ3 2026-$0.14
MBIO diluted EPS was -$0.14 in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$0.07 a year earlier. For the full fiscal 2025 it was -$0.39.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | - | $7.56M | $40.51M | $62.48M | $49.86M | $37.24M | $30.04M | $21.10M | $7.94M | $2.47M |
| Selling, general and admin | $3.95M | $4.13M | $9.69M | $12.21M | $11.02M | $9.51M | $9.57M | $6.76M | $11.41M | $2.82M |
| Operating income | -$2.43M | -$16.25M | -$49.26M | -$76.16M | -$66.72M | -$56.81M | -$45.88M | -$31.22M | -$31.79M | -$11.36M |
| Pre-tax income | -$1.92M | -$15.75M | - | - | - | - | - | - | - | - |
| Income tax | $27.0K | - | - | - | - | - | - | - | - | - |
| Net income | -$1.92M | -$15.75M | -$51.60M | -$77.53M | -$66.37M | -$60.02M | -$46.39M | -$30.66M | -$31.29M | -$12.65M |
| EPS, basic | -$0.39 | -$38.57 | -$15597.40 | -$524.68 | -$533.52 | -$800.28 | -$905.58 | -$800.28 | -$870.48 | -$807.30 |
| EPS, diluted | -$0.39 | -$38.57 | -$15597.40 | -$524.68 | -$533.52 | -$800.28 | -$905.58 | -$800.28 | -$870.48 | -$807.30 |
| Diluted shares | 4.9M | 609,696 | 3,308.288 | 147,779 | 125,192.642 | 74,912.793 | 51,370.101 | 38,389.422 | 35,972.695 | 15,707.501 |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $17.27M | $6.84M | $6.98M | $76.66M | $110.62M | $98.80M | $62.41M | $16.97M | $35.48M | $27.50M |
| Short-term investments | - | - | - | - | - | - | $0 | $17.60M | - | - |
| Current assets | $17.59M | $8.61M | $11.35M | $78.85M | $111.71M | $99.53M | $63.06M | $35.13M | $61.36M | $27.50M |
| Total assets | $17.59M | $9.31M | $17.74M | $92.42M | $125.17M | $109.90M | $73.44M | $42.75M | $63.49M | $27.50M |
| Current liabilities | $7.91M | $12.61M | $15.37M | $15.11M | $10.81M | $9.52M | $7.77M | $5.62M | $3.61M | $3.22M |
| Short-term debt | - | - | - | - | - | $0 | $1.25M | $0 | - | - |
| Total debt | - | - | - | - | - | - | $13.43M | $0 | - | - |
| Total liabilities | $8.06M | $13.18M | $17.62M | $46.15M | $12.77M | $11.46M | $21.79M | $6.36M | $3.66M | $3.22M |
| Shareholders' equity | $9.53M | -$3.87M | $123.0K | $46.27M | $112.40M | $98.44M | $51.65M | $36.40M | $59.83M | $24.28M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$5.26M | -$11.41M | -$49.48M | -$65.07M | -$53.67M | -$37.32M | -$33.58M | -$19.24M | -$12.95M | -$4.13M |
| Capital expenditures | - | $0 | $64.0K | $2.71M | $3.99M | $1.93M | $2.35M | $6.87M | $424.0K | - |
| Free cash flow | - | -$11.41M | -$49.54M | -$67.78M | -$57.65M | -$39.24M | -$35.93M | -$26.11M | -$13.37M | - |
| Investing cash flow | $1.17M | $0 | $5.89M | -$2.95M | -$5.37M | -$4.41M | $13.91M | $557.0K | -$29.05M | $0 |
| Financing cash flow | $14.53M | $11.27M | -$26.08M | $34.06M | $70.85M | $78.12M | $65.12M | $181.0K | $49.98M | $31.63M |
| Stock-based compensation | $129.0K | -$450.0K | $568.0K | $2.28M | $3.31M | $2.99M | $2.66M | $4.96M | $2.01M | $0 |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on equity | -20.2% | - | -41952.8% | -167.5% | -59.0% | -61.0% | -89.8% | -84.2% | -52.3% | -52.1% |
| Return on assets | -10.9% | -169.2% | -290.8% | -83.9% | -53.0% | -54.6% | -63.2% | -71.7% | -49.3% | -46.0% |
| Current ratio | 2.22 | 0.68 | 0.74 | 5.22 | 10.33 | 10.46 | 8.12 | 6.25 | 16.99 | 8.53 |
| Debt to equity | - | - | - | - | - | - | 0.26 | 0.00 | - | - |
Income statement
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | - | - | - | - | - | - | - | -$664.0K | $57.0K | $4.36M | $3.80M | $6.15M |
| Selling, general and admin | $850.0K | $946.0K | $880.0K | $987.0K | $957.0K | $787.0K | $1.22M | -$223.0K | $1.40M | $1.53M | $1.43M | $2.18M |
| Operating income | -$1.06M | -$1.17M | -$1.06M | -$670.0K | -$624.0K | -$885.0K | -$253.0K | -$1.02M | -$1.46M | -$8.54M | -$5.23M | -$8.74M |
| Net income | -$964.0K | -$1.07M | -$955.0K | -$538.0K | -$468.0K | -$762.0K | -$153.0K | -$952.0K | -$1.41M | -$8.20M | -$5.19M | -$8.62M |
| EPS, basic | -$0.14 | -$0.16 | -$0.14 | - | -$0.07 | -$0.19 | -$0.05 | - | -$1.96 | -$18.36 | -$1290.12 | - |
| EPS, diluted | -$0.14 | -$0.16 | -$0.14 | - | -$0.07 | -$0.19 | -$0.05 | - | -$1.96 | -$18.36 | -$1290.12 | - |
| Diluted shares | 6.7M | 6.7M | 6.7M | - | 6.2M | 4.0M | 2.9M | - | 720,911 | 446,587 | 4,023.096 | - |
Balance sheet
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $14.28M | $15.15M | $16.26M | $17.27M | $18.98M | $12.66M | $14.23M | $6.84M | $3.90M | $4.64M | $1.71M | $6.98M |
| Current assets | - | - | - | $17.59M | $19.36M | $13.05M | $14.91M | $8.61M | $6.05M | $7.32M | $9.24M | $11.35M |
| Total assets | $14.68M | $15.61M | $16.58M | $17.59M | $19.36M | $13.05M | $14.91M | $9.31M | $7.19M | $8.52M | $14.59M | $17.74M |
| Current liabilities | $7.95M | $7.92M | $7.84M | $7.91M | $9.44M | $10.00M | $11.15M | $12.61M | $15.04M | $15.92M | $17.44M | $15.37M |
| Total liabilities | $8.10M | $8.07M | $7.99M | $8.06M | $9.59M | $10.15M | $11.30M | $13.18M | $15.85M | $16.85M | $19.54M | $17.62M |
| Shareholders' equity | $6.59M | $7.54M | $8.60M | $9.53M | $9.77M | $2.89M | $3.61M | -$3.87M | -$8.66M | -$8.33M | -$4.94M | $123.0K |
Cash flow
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$876.0K | -$967.0K | -$1.01M | -$1.72M | -$818.0K | -$1.34M | -$1.39M | -$2.00M | -$1.76M | -$2.33M | -$5.32M | -$7.25M |
| Capital expenditures | - | - | - | - | - | - | - | $0 | $0 | - | - | $30.0K |
| Free cash flow | - | - | - | - | - | - | - | -$2.00M | -$1.76M | - | - | -$7.28M |
| Investing cash flow | $0 | $0 | $0 | $0 | $0 | $0 | $1.17M | $0 | $0 | $0 | $0 | -$30.0K |
| Financing cash flow | $2.0K | -$141.0K | $0 | $0 | $7.14M | -$235.0K | $7.62M | $4.94M | $1.01M | $5.27M | $49.0K | $3.96M |
| Stock-based compensation | $2.0K | $21.0K | $22.0K | $23.0K | $23.0K | $45.0K | $38.0K | $50.0K | $42.0K | -$619.0K | $76.0K | $188.0K |
Key ratios
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | - | - | - | 2.22 | 2.05 | 1.30 | 1.34 | 0.68 | 0.40 | 0.46 | 0.53 | 0.74 |
Source: XBRL data Mustang Bio Inc. files with the SEC, latest filing dated Nov 5, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures and share counts are restated for stock splits the filings show: 2-for-27, first reported Aug 14, 2023; 1-for-52, first reported Aug 8, 2025.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
MBIO peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| MBIO | - | - | -$3.53M | - | $3.4M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.35T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $675.92B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $519.48B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $364.98B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $311.52B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $289.61B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $191.31B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $180.22B |
MBIO FAQ
4 questionsIs MBIO profitable?
No. Mustang Bio Inc. reported a net loss of $3.53M for the twelve months ended Sep 30, 2026.How much cash and debt does MBIO have?
Mustang Bio Inc. reported $14.28M in cash and cash equivalents on its most recent balance sheet in SEC filings.When did MBIO last report financial results?
The latest statements here come from Mustang Bio Inc.'s 10-Q filed on Nov 5, 2026, covering the period ended Sep 30, 2026.Where does this MBIO financial data come from?
Quantisnow builds these statements from the structured XBRL data Mustang Bio Inc. files with the SEC. It is provided for information only and is not investment advice.